Abstract
Sickle Cell Anemia (SCA) is a genetic hemoglobinopathy characterized by chronic hemolytic anemia, pain and damage to various organs, leading to wide clinical variability and decreased life expectancy. Increased levels of fetal hemoglobin (HbF) is a validated approach to treatment. Among the strategies described to elevate HbF levels, the inhibition of the enzymes Histone Deacetylase (HDAC…